--- title: "Analyst Reiterates Buy on Caribou Biosciences, Keeps $8 Price Target After Encouraging Allo CAR-T Data" type: "News" locale: "en" url: "https://longbridge.com/en/news/289527445.md" description: "Citi analyst Yigal Nochomovitz reiterated a Buy rating on Caribou Biosciences with an $8 price target, citing encouraging allo CAR-T data from EHA 2026. Positive results for vispa-cel in LBCL and CB-011 in multiple myeloma, including high response rates and favorable safety profiles, support the outlook ahead of pivotal Phase 3 trials. Bank of America also maintained a Buy rating with a $6 target." datetime: "2026-06-12T00:25:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289527445.md) - [en](https://longbridge.com/en/news/289527445.md) - [zh-HK](https://longbridge.com/zh-HK/news/289527445.md) --- # Analyst Reiterates Buy on Caribou Biosciences, Keeps $8 Price Target After Encouraging Allo CAR-T Data Analyst Yigal Nochomovitz from Citi maintained a Buy rating on Caribou Biosciences and keeping the price target at $8.00. ### Introducing TipRanks MCP for Agents - Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. - Designed for personal research, portfolio monitoring, and AI-assisted investment workflows. Yigal Nochomovitz has given his Buy rating due to a combination of factors related to Caribou Biosciences’ emerging allo CAR-T portfolio and the strength of new clinical data. At EHA 2026, the company reported extended follow-up for vispa-cel in second-line LBCL showing high overall and complete response rates, now coupled with a median progression-free survival of 17.1 months, while maintaining a safety profile compatible with outpatient use and broader community adoption. Additionally, CB-011 continued to show deep and durable responses in heavily pre-treated, BCMA-naïve R/R multiple myeloma patients at the selected recommended dose, with high complete response, overall response, and MRD negativity rates and no signal of serious allo-specific toxicities such as GvHD or immune effector cell–associated complications. With a pivotal Phase 3 trial for vispa-cel being prepared, ongoing CB-011 expansion cohorts, and the overall dataset reinforcing the allo CAR-T value proposition, Nochomovitz sees substantial upside potential and keeps his price target unchanged at $8, supporting a Buy rating on this high-risk, high-reward name. Nochomovitz covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Travere Therapeutics, and ACADIA Pharmaceuticals. According to TipRanks, Nochomovitz has an average return of 7.6% and a 42.34% success rate on recommended stocks. In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $6.00 price target. ### Related Stocks - [CRBU.US](https://longbridge.com/en/quote/CRBU.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [OLMA.US](https://longbridge.com/en/quote/OLMA.US.md) - [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md) - [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [Equities Analysts Set Expectations for CRBU Q3 Earnings](https://longbridge.com/en/news/296219683.md) - [Caribou Biosciences Q2 net loss narrows](https://longbridge.com/en/news/295849330.md) - [Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft](https://longbridge.com/en/news/296352331.md) - [ALLO: Allogeneic CAR T platform shows strong efficacy, safety, and broad market potential across key indications](https://longbridge.com/en/news/295718267.md) - [Imugene shareholders back capital-raising resolutions at extraordinary meeting](https://longbridge.com/en/news/296287728.md)